Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

What the heck just happened? Well, you read a really good movie tagline. This micro–art form is a great way to sell someone on experiencing a story. Knowing how to craft an effective tagline is ...

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company ...

At a campaign event last week for GOP presidential candidate Donald Trump and his running mate JD Vance, attendees waved placards emblazoned with a slogan that is also used by a notorious white ...

The agreement grants Merck the option to license Evaxion’s preclinical vaccine candidates EVX-B2 and EVX-B3. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 ...

What better way to celebrate the fact that there's less than a week to go until the Season 15 premiere of The Real Housewives of New York City than by unveiling the ladies' new taglines?